肿瘤细胞治疗研究
英文原题：CARs for lymphoma.
嵌合抗原受体（CAR）-T细胞疗法已经彻底改变了B细胞非霍奇金淋巴瘤（NHL）的治疗选择。
嵌合抗原受体（CAR）-T细胞疗法已经彻底改变了B细胞非霍奇金淋巴瘤（NHL）的治疗选择。靶向CD19的CAR-T细胞疗法已获批用于治疗弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤、套细胞淋巴瘤以及慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。CAR-T细胞即使在经过大量预处理的患者中也表现出强效且持久的缓解。临床医生应监测细胞因子释放综合征（CRS）和免疫效应细胞神经毒性综合征（ICANS），以及血细胞减少、感染和第二恶性肿瘤。在提高生产效率、CAR-T细胞与其他疗法（包括双特异性抗体（BiTEs））的排序，以及预测最佳应答者方面，仍存在有待解决的问题。此外，正在开发具有替代靶点或分泌激活性细胞因子的新型CAR（即“装甲CAR”）。CAR-T细胞代表一种有效的淋巴瘤疗法，应考虑用于符合条件的患者。
Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized treatment options for B-cell Non-Hodgkin Lymphoma (NHL). CD19-targeting CAR-T cell therapy is approved for treatment in Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. CAR-T cells demonstrate robust and durable responses even in heavily pretreated patients. Clinicians should monitor for Cytokine Release Syndrome (CRS) and Immune Effector Cell Neurotoxicity Syndrome (ICANS), as well as cytopenias, infection, and secondary malignancies. Ongoing questions remain in improving manufacturing efficacy, sequencing CAR-T cells amongst other therapies including bi-specific antibodies (BiTEs), and predicting optimal responders. In addition, novel CARs are being developed with alternative targets or that secrete activating cytokines (i.e. "armored CARs"). CAR-T cells represent an effective lymphoma therapy and should be considered for eligible patients.
MEMBER ACCOUNT
登录成功会直接打开下一页。
